Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 ,inter alia, to consider and approve Audited Financial Results for the ....

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+12.2%Reaction day

₹90.65

prior close

₹96.72

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%+11.1% vs market

Pharmaceuticals peers, median of 150sector+1.0%+11.3% vs sector

On the reaction day the stock moved 11.1 pts more than Nifty Microcap 250 and 11.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+2.1

15m

+2.4

30m

+4.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+12.2+1.2+11.1+1.0+11.3

Next day

+15.0+0.1+14.9-0.2+15.2

+16.6+0.9+15.7+0.5+16.0

+17.8+0.8+17.0+0.1+17.7

+10.9+1.4+9.4+0.1+10.7

+13.7+2.0+11.7+0.5+13.2

+17.5+2.3+15.2+1.5+16.0

15d

+17.7+5.2+12.6+1.4+16.3

+14.9+1.6+13.4-1.5+16.4

+14.8+7.7+7.1+3.5+11.3

-3.3+4.0-7.3-0.2-3.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma has called a Board Meeting on 23rd May, 2025 with a packed agenda. The main items are approval of audited financial results for Q4 and full year ended 31st March, 2025, and a recommendation on dividend for FY25. The Board will also consider a proposal to issue bonus shares, subject to shareholder and other approvals. Additionally, it will re-appoint Joint Managing Directors Ritesh Shah and Vivek Shah, re-appoint two directors retiring by rotation, and appoint a new Secretarial Auditor for a five-year term (FY26 to FY30). The trading window for insiders is closed from 1st April until 25th May, 2025, i.e., 48 hours after results are declared.

Likely market impact

Investors should watch for the Q4/FY25 results and the bonus share proposal on 23rd May, as bonus issues typically lift retail interest and can lead to a short-term price adjustment. Dividend, if declared, will add to near-term return expectations.

By the numbersStandalone · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹198.1 Cr	₹163.9 Cr	+20.9%
Operating profit	₹15.88 Cr	₹16.90 Cr	−6.0%
Profit after tax	₹12.46 Cr	₹15.36 Cr	−18.9%
EBITDA margin	9.4%	11.7%	−2.3 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.